Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts is a research paper published in Neuro-Oncology Advances (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Boehringer Ingelheim, National Institutes of Health/National Cancer Institute
Grant: U19-CA264362
NCI NIH HHS
Grant: R01 CA285536
NCI NIH HHS
Grant: U19 CA264362
FWCI
0.00
Citation Percentile
0.5%
Fields of Study
Keywords